DSpace Repositorium (Manakin basiert)

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Zur Kurzanzeige

dc.contributor.author Anker, Stefan D.
dc.contributor.author Butler, Javed
dc.contributor.author Usman, Muhammad Shariq
dc.contributor.author Filippatos, Gerasimos
dc.contributor.author Ferreira, João Pedro
dc.contributor.author Bocchi, Edimar
dc.contributor.author Böhm, Michael
dc.contributor.author Brunner-La Rocca, Hans Pieter
dc.contributor.author Choi, Dong-Ju
dc.contributor.author Chopra, Vijay
dc.contributor.author Chuquiure, Eduardo
dc.contributor.author Giannetti, Nadia
dc.contributor.author Gomez-Mesa, Juan Esteban
dc.contributor.author Janssens, Stefan
dc.contributor.author Januzzi, James L.
dc.contributor.author González-Juanatey, José R.
dc.contributor.author Merkely, Bela
dc.contributor.author Nicholls, Stephen J.
dc.contributor.author Perrone, Sergio Víctor
dc.contributor.author Piña, Ileana L.
dc.date.accessioned 2023-01-02T13:06:22Z
dc.date.available 2023-01-02T13:06:22Z
dc.date.issued 2022-12
dc.identifier.citation Anker SD, Butler J, Usman MS, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Rocca HPB, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, González-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Iwata T, Schnee JM, Brueckmann M, Pocock SJ, Zannad F. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. Nat Med. 2022 Dec;28(12):2512-2520. doi: 10.1038/s41591-022-02041-5. Epub 2022 Dec 5. es_ES
dc.identifier.uri https://doi.org/10.1038/s41591-022-02041-5
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/750
dc.description.abstract The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) (n = 4,005; 66.9%) or mid-range (41-49%). In patients with LVEF ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71-0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66-1.04, P = 0.11). For patients with an LVEF of 41-49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57-0.88, P = 0.002) for the primary outcome (Pinteraction = 0.27), and 0.57 (95%CI: 0.42-0.79, P < 0.001) for total HHF (Pinteraction = 0.06). These results, together with those from the EMPEROR-Reduced trial in patients with LVEF < 40%, support the use of empagliflozin across the full spectrum of LVEF in heart failure. es_ES
dc.language.iso eng es_ES
dc.publisher Nature Publishing Company es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Benzhydryl Compounds es_ES
dc.subject Compuestos de Bencidrilo es_ES
dc.subject Heart Failure es_ES
dc.subject Insuficiencia Cardíaca es_ES
dc.title Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Perrone, Sergio Víctor. Fleni. Departamento de Neurología. Servicio de Cardiología; Argentina. Instituto Argentino de Diagnóstico y Tratamiento; Argentina.
dc.description.fil Fil: Butler, Javed. Baylor Scott and White Research Institute; Estados Unidos. University of Mississippi; Estados Unidos. Wrocław Medical University. Institute of Heart Diseases; Estados Unidos.
dc.description.fil Fil: Anker, Stefan D. German Centre for Cardiovascular Research; Alemania. Wrocław Medical University. Institute of Heart Diseases; Estados Unidos.
dc.description.fil Fil: Usman, Muhammad Shariq. University of Mississippi Medical Center; Estados Unidos.
dc.description.fil Fil: Filippatos, Gerasimos. National and Kapodistrian University of Athens School of Medicine; Grecia.
dc.description.fil Fil: Ferreira, João Pedro. Université de Lorraine; Francia. Faculty of Medicine of the University of Porto. Department of Surgery and Physiology. Cardiovascular Research and Development Center; Portugal.
dc.description.fil Fil: Bocchi, Edimar. Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo. Instituto do Coracao. Heart Failure Clinics; Brasil.
dc.description.fil Fil: Böhm, Michael. Universitätsklinikum des Saarlandes; Alemania.
dc.description.fil Fil: Brunner-La Rocca, Hans Pieter. Maastricht University Medical Center; Países Bajos. School for Cardiovascular Disease CARIM; Países Bajos.
dc.description.fil Fil: Choi, Dong-Ju. Seoul National University Bundang Hospital. Department of Medicine; Corea del Sur.
dc.description.fil Fil: Chopra, Vijay. Max Superspeciality Hospital; India.
dc.description.fil Fil: Chuquiure, Eduardo. National Institute of Cardiology; México.
dc.description.fil Fil: Giannetti, Nadia. McGill University Health Centre; Canadá.
dc.description.fil Fil: Gomez-Mesa, Juan Esteban. Universidad Icesi Cali. Fundación Valle del Lili. Cardiology Service; Colombia.
dc.description.fil Fil: Janssens, Stefan. University Hospitals Leuven. Department of Cardiovascular Diseases; Bélgica.
dc.description.fil Fil: Januzzi, James L. Massachusetts General Hospital and Baim Institute for Clinical Research; Estados Unidos.
dc.description.fil Fil: González-Juanatey, José R. University Hospital. Cardiology Department; España.
dc.description.fil Fil: Merkely, Bela. Semmelweis University. Heart and Vascular Center; Hungría.
dc.description.fil Fil: Nicholls, Stephen J. Monash University. Victorian Heart Institute; Australia.
dc.description.fil Fil: Piña, Ileana L. Central Michigan University; Estados Unidos.
dc.relation.ispartofVOLUME 28
dc.relation.ispartofNUMBER 12
dc.relation.ispartofPAGINATION 2512-2520.
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Nueva York
dc.relation.ispartofTITLE Nature medicine
dc.relation.ispartofISSN 1546-170X
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Dateien zu dieser Ressource

Das Dokument erscheint in:

Zur Kurzanzeige

info:eu-repo/semantics/openAccess Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: info:eu-repo/semantics/openAccess

DSpace Suche


Stöbern

Mein Benutzerkonto

Statistik